AccuStem Sciences Company Description

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care.

It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant.

The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients.

The company has a partnership with EmeritusDX for the development of non-invasive blood testing technologies.

AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

AccuStem Sciences, Inc.

Country	United States
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	2
CEO	Wendy Blosser

Contact Details

Address: 5 Penn Plaza New York, Delaware 10001 United States
Website	accustem.com

Stock Details

Ticker Symbol	ACUT
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US00444A1016
SIC Code	2836

Key Executives

Name	Position
Wendy E. Blosser	Chief Executive Officer and Director
Gabriele Marco Antonio Cerrone M.B.A.	Executive Chairman of the Board
Joe Flanagan	Chief Business Officer
Keeren Shah	Chief Financial Officer